Page 3 - Phasei Program News Today

Martin E. Gutierrez, MD, and Lori A. Leslie, MD, discuss common barriers to implementing CAR T-cell therapy programs, early successes that John Theurer Cancer Center in New Jersey has seen with outpatient CAR T-cell therapy administration, and developments on the horizon for administering this approach in solid tumors

Funda Meric-Bernstam, MD, discusses the safety of CBX-12 and exploring dosage of the agent.

Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike.

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

Kathleen N. Moore, MD, MS, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study of ubamatamab, a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 -- Affimed N.V. ...